What is the NAD-HD study and what does it mean for you?
– Written by the Moving Forward team on 6th May 2026
On 14 April, Moving Forward, in collaboration with the Norwegian Huntington’s Disease Association and Oslo University Hospital, organised a webinar on the NAD-HD study at Rikshospitalet in Oslo. Around 50 people had registered, and just under 40 took part.
The webinar was chaired by the president of the European Huntington’s Disease Association, Astri Arnesen. She opened by introducing the speakers before Lasse Pihlstrøm, a researcher and senior consultant at the Neurology Outpatient Clinic at Rikshospitalet, took over. He is the lead investigator for the NAD-HD study and gave a thorough overview of the study, including information about the medication being tested, how to be included, as well as the current status and future plans, including the launch in Bergen.
Several questions had been submitted in advance, and further questions were also asked during the webinar. These were answered by Pihlstrøm.
Following the presentation, participants heard experiences from three study participants and one family member. Astri Arnesen asked them several questions, and the feedback was consistently very positive. The participants expressed satisfaction with the follow-up they had received and felt they had been given good and clear information about the study. It is relatively rare for study participants to share their experiences from studies related to Huntington’s disease, which made this part particularly valuable.
Around 15 of the participants were attending a webinar on Huntington’s disease for the very first time, which we view as very positive.
Watch the recording below: